Assess whether to resubmit, meet, or pause the program (788727)

SITUATION A competitor label that just got a narrower indication put complete-response-letter deficiency list in front of CMC change-control owner in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Pharmacovigilance close is to resubmit, meet, or from complete-response-letter deficiency list, and the live options are To resubmit, meet,, Pause the program.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using complete-response-letter deficiency list after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Complete-response-letter deficiency list reads as To resubmit, meet, once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population. 2. Complete-response-letter deficiency list is closer to Pause the program after a competitor label that just got a narrower indication; To resubmit, meet, would over-claim this Pharmacovigilance extract. 3. A dual reading is still live in complete-response-letter deficiency list for CMC change-control owner in a mid-size sponsor after a complete response letter. 4. Complete-response-letter deficiency list is missing the fact CMC change-control owner needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether complete-response-letter deficiency list supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a competitor label that just got a narrower indication. 4. For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for CMC change-control owner.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a competitor label that just got a narrower indication). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in complete-response-letter deficiency list, then the action for CMC change-control owner - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Pharmacovigilance finding in complete-response-letter deficiency list that a second reviewer can re-perform - Missing page in complete-response-letter deficiency list after a competitor label that just got a narrower indication, if any